Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation.

Clinical chemistry - 1 Oct 2006

Guardiola Montse, Ferré Raimon, Salazar Juliana, Alonso-Villaverde Carlos, Coll Blai, Parra Sandra, Masana Lluís, Ribalta Josep

Abstract excerpt

BACKGROUND: Hyperlipidemia associated with the protease inhibitor (PI) component of highly active antiretrovial treatment can lead to accelerated atherosclerosis. The apolipoprotein A-V (APOA5) gene, which affects VLDL production and lipolysis, may play a role in PI-induced hyperlipidemia, particularly in individuals with the APOA5-1131T-->C genotype. METHODS: We measured lipoprotein changes in HIV-positive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoprotein A-V
Share to Apolipoproteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apolipoproteins A

Share to HIV Infections

Share to HIV Protease Inhibitors

Share to Hyperlipidemias

Share to Lipids

Share to Longitudinal Studies

Source

Identifiers

PMID: 16887900
DOI: 10.1373/clinchem.2006.069583

Genes

APOA5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation.PMID 16887900Read ↗

Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy.Semantic proximity Read ↗

An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients.Semantic proximity Read ↗

Contribution of APOA5, APOC3, CETP, ABCA1 and SIK3 genetic variants to hypertriglyceridemia development in Mexican HIV-patients receiving antiretroviral therapy.Semantic proximity Read ↗

Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner.Semantic proximity Read ↗

Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.Semantic proximity Read ↗

Genetic markers associated to dyslipidemia in HIV-infected individuals on HAART.Semantic proximity Read ↗

Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy.Semantic proximity Read ↗

Association between polymorphisms in genes involved in lipid metabolism and immunological status in chronically HIV-infected patients.Semantic proximity Read ↗

The ACTN3 R577X polymorphism affects the lipid profile and the prognosis of nutritional intervention in HIV-positive patients.Semantic proximity Read ↗

Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders.Semantic proximity Read ↗

Association of immune recovery with hyperlipidaemia and apolipoprotein gene polymorphisms following highly active antiretroviral therapy in a cohort of Chinese HIV patients.Semantic proximity Read ↗

Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.